ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
Pharma 5.0 시장 규모는 최근 몇 년간 크게 성장했습니다. 2025년 783억 1,000만 달러에서 2026년에는 831억 2,000만 달러에 이르고, CAGR 6.1%의 성장이 전망되고 있습니다. 지금까지의 성장 요인으로는 전통적인 제약 R&D 프로세스에 대한 의존도, 제한적인 디지털 툴 도입, 개인 맞춤형 치료에 대한 수요 증가, 환자 결과에 대한 규제 당국의 관심 증가, 전통적인 제조 기술에 대한 투자 등을 꼽을 수 있습니다.
향후 몇 년간으로, Pharma 5.0 시장 규모는 견고성장이 전망됩니다. 2030년에는 1,043억 2,000만 달러에 이르고, CAGR은 5.8%를 나타낼 전망입니다. 예측 기간 동안 성장 요인으로는 AI 기반 신약개발 플랫폼 도입, 클라우드 기반 헬스케어 솔루션 확대, 제조 공정에서 RPA(로봇 프로세스 자동화)와 디지털 트윈의 통합, 유전체 분석 및 약리유전체학 도입 확대, 제약회사와 디지털 헬스 스타트업 간 협력 강화 등을 꼽을 수 있습니다. 예측 기간 동안 주요 동향으로는 환자 중심 디지털 헬스케어 솔루션의 통합, 정밀의료 및 개인 맞춤형 치료 계획의 성장, 제약업계의 스마트 제조 및 자동화 도입, 원격 모니터링 및 가상 헬스케어 플랫폼의 확대, 의약품 개발 및 임상시험에서 예측 분석의 활용 증가 등이 있습니다. 증가 등을 꼽을 수 있습니다.
디지털 헬스 기술의 급격한 성장은 약국 5.0 시장의 원동력이 될 것으로 보입니다. 디지털 헬스 기술은 디지털 인터페이스, 앱, 가젯을 활용한 다양한 도구와 시스템을 포괄하며, 의료 제공의 효율성, 환자 성과 향상, 의료 업무의 최적화를 도모합니다. 이러한 성장은 언제 어디서나 의료 서비스를 이용할 수 있는 원격 진료 옵션에 대한 수요가 증가하고 있기 때문입니다. Pharma 5.0은 AI 분석, 개인화 치료, 자동화를 융합하여 환자 모니터링의 정확성, 치료의 정확성, 서비스 속도를 높이고, 디지털 헬스를 보완합니다. 예를 들어, 2024년 10월 미국 비영리 의료 정책 단체인 카이저 가족 재단(KFF)이 발표한 조사에 따르면, 메디케어 이용자의 원격의료 이용률은 그룹별로 차이를 보였는데, 도시 지역 27%, 농촌 지역 19%, 인종별로는 아시아/태평양 섬 지역 31%, 히스패닉계 30%, 흑인 30%, 미국 원주민/알래스카 원주민 25%, 비히스패닉 백인 24%로 나타났습니다. 30%, 흑인 26%, 미국 원주민/알래스카 원주민 25%, 비히스패닉계 백인 24% 순으로 디지털 헬스 이용률이 높은 것으로 나타났습니다. 이처럼 디지털 헬스의 급격한 성장이 Pharma 5.0 시장을 주도하고 있습니다.
제약 5.0 시장의 주요 기업들은 창발적 인공지능(AI) 클라우드 서비스와 같은 첨단 툴을 통해 의약품 개발 가속화, 임상시험의 정교화, 치료의 개인화, 워크플로우의 효율화를 추구하고 있습니다. 창발형 인공지능(AI) 클라우드 서비스는 데이터 세트 내 패턴 인식에서 새로운 데이터-분석-설계를 생성하는 AI를 활용한 온라인 플랫폼입니다. 예를 들어, 2023년 3월 미국의 기술 선도기업인 NVIDIA는 생명과학 연구개발에 혁명을 가져올 획기적인 생성형 AI 플랫폼인 'BioNeMo Cloud'를 발표했습니다. 암젠, 아스트라제네카 등 생명공학 대기업과 공동 개발한 이 플랫폼은 생체 분자 과제에 특화된 대규모 언어 모델(LLM)을 제공하여 단백질 구조 예측, 분자 결합, 신약 후보물질 탐색을 가속화합니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 공급망 분석
제4장 세계 시장 동향과 전략
제5장 최종 이용 산업 시장 분석
제6장 시장 : 금리, 인플레이션, 지정학, 무역 전쟁과 관세의 영향, 관세 전쟁과 무역 보호주의의 공급망에 대한 영향, 코로나 팬데믹이 시장에 미치는 영향을 포함한 거시경제 시나리오
제7장 세계 전략 분석 프레임워크, 현재 시장 규모, 시장 비교 및 성장률 분석
제8장 TAM(Total Addressable Market) 규모
제9장 시장 세분화
제10장 지역별/국가별 분석
제11장 아시아태평양 시장
제12장 중국 시장
제13장 인도 시장
제14장 일본 시장
제15장 호주 시장
제16장 인도네시아 시장
제17장 한국 시장
제18장 대만 시장
제19장 동남아시아 시장
제20장 서유럽 시장
제21장 영국 시장
제22장 독일 시장
제23장 프랑스 시장
제24장 이탈리아 시장
제25장 스페인 시장
제26장 동유럽 시장
제27장 러시아 시장
제28장 북미 시장
제29장 미국 시장
제30장 캐나다 시장
제31장 남미 시장
제32장 브라질 시장
제33장 중동 시장
제34장 아프리카 시장
제35장 시장 규제 상황과 투자환경
제36장 경쟁 구도와 기업 개요
제37장 기타 주요 기업 및 혁신 기업
제38장 세계 시장 경쟁 벤치마킹과 대시보드
제39장 주요 인수합병(M&A)
제40장 시장 잠재력이 높은 국가, 부문, 전략
제41장 부록
LSH
영문 목차
영문목차
Pharma 5.0 refers to the next generation of pharmaceutical development that integrates advanced digital technologies with patient-centric healthcare solutions. It emphasizes precision treatment, automation, and data-driven decision-making to enhance therapeutic outcomes, reduce costs, and improve operational efficiency across the pharmaceutical value chain.
The main types of Pharma 5.0 solutions include personalized medicine platforms, digital therapeutics, artificial intelligence (AI)-driven drug discovery, smart manufacturing, and AI-based diagnostics. Personalized medicine platforms leverage individual genetic, environmental, and lifestyle data to tailor medical treatments specifically to each patient. These platforms utilize advanced technologies such as cloud computing, artificial intelligence (AI), machine learning (ML), the Internet of Things (IoT), and robotic process automation (RPA). They are deployed in various modes, including on-premise and cloud-based systems, and are applied across therapeutic areas such as cardiovascular diseases, oncology, infectious diseases, neurology, and others. Key end users include pharmaceutical and biotechnology companies, healthcare providers, contract research organizations (CROs), and academic or research institutes.
Tariffs have impacted the Pharma 5.0 market by increasing costs of imported high-tech equipment, AI software platforms, and cloud infrastructure essential for digital drug discovery and smart manufacturing. Segments such as AI-driven drug discovery, smart manufacturing, and digital therapeutics are most affected, particularly in North America, Europe, and Asia-Pacific regions dependent on imports. While tariffs have raised operational costs and slowed technology adoption, they have also encouraged local development of AI tools, cloud infrastructure, and digital health innovations, promoting domestic capabilities and reducing long-term dependency on imports.
The pharma 5.0 market research report is one of a series of new reports from The Business Research Company that provides pharma 5.0 market statistics, including pharma 5.0 industry global market size, regional shares, competitors with a pharma 5.0 market share, detailed pharma 5.0 market segments, market trends and opportunities, and any further data you may need to thrive in the pharma 5.0 industry. This pharma 5.0 market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The pharma 5.0 market size has grown strongly in recent years. It will grow from $78.31 billion in 2025 to $83.12 billion in 2026 at a compound annual growth rate (CAGR) of 6.1%. The growth in the historic period can be attributed to reliance on traditional pharmaceutical R&D processes, limited adoption of digital tools, growing demand for personalized therapies, increasing regulatory focus on patient outcomes, investment in conventional manufacturing technologies.
The pharma 5.0 market size is expected to see strong growth in the next few years. It will grow to $104.32 billion in 2030 at a compound annual growth rate (CAGR) of 5.8%. The growth in the forecast period can be attributed to deployment of ai-driven drug discovery platforms, expansion of cloud-based healthcare solutions, integration of rpa and digital twins in manufacturing, rising adoption of genomic sequencing and pharmacogenomics, increasing collaboration between pharma and digital health startups. Major trends in the forecast period include integration of patient-centric digital health solutions, growth in precision medicine and personalized treatment plans, adoption of smart manufacturing and automation in pharma, expansion of remote monitoring and virtual healthcare platforms, increasing use of predictive analytics for drug development and clinical trials.
The boom in digital health technologies is poised to drive the pharmacy 5.0 market forward. Digital health technologies encompass diverse tools and systems leveraging digital interfaces, apps, and gadgets to streamline care delivery, elevate patient results, and optimize health operations. Their growth stems from escalating needs for remote care options offering anytime, anywhere medical access. Pharma 5.0 complements digital health by fusing AI analytics, custom therapies, and automation to sharpen patient surveillance, treatment precision, and service speed. For example, in October 2024, the Kaiser Family Foundation (KFF), a US non-profit health policy group, highlighted telehealth use among Medicare users varying by group: 27% urban versus 19% rural; by ethnicity, 31% Asian/Pacific Islander, 30% Hispanic, 26% Black, 25% American Indian/Alaska Native, and 24% non-Hispanic White-signaling lasting digital health uptake. Thus, the digital health surge is powering the pharmacy 5.0 market.
Top companies in the pharma 5.0 market are advancing sophisticated tools like generative artificial intelligence (AI) cloud services to hasten drug development, refine trials, tailor treatments, and streamline workflows. Generative artificial intelligence (AI) cloud services are online platforms harnessing AI to generate fresh data, analyses, or designs from pattern recognition in datasets. For instance, in March 2023, NVIDIA Corporation, a US tech leader, debuted BioNeMo Cloud, a game-changing generative AI platform revolutionizing life sciences R&D. Co-created with biotech giants like Amgen and AstraZeneca, it supplies specialized large language models (LLMs) for biomolecular tasks, speeding protein structure forecasts, molecular bonds, and new drug prospects.
In May 2025, AstraZeneca plc, a UK pharmaceutical powerhouse, bought EsoBiotec BV for an undisclosed sum. This move accelerates EsoBiotec's trailblazing in vivo cell therapy tech, slashing treatment timelines from weeks to minutes, broadening affordable, scalable options for cancer and immune disorders worldwide. EsoBiotec BV is a Belgium-based biotech innovator in AI-driven in vivo cell therapies.
Major companies operating in the pharma 5.0 market are Pfizer Incorporated, Johnson & Johnson, Roche Holding AG, Sanofi S.A., Bristol Myers Squibb Company, AstraZeneca Plc, Novartis AG, GSK Plc, Eli Lilly and Company, Ericsson AB, Merck KGaA, Moderna Inc., BioNTech SE, Teva Pharmaceuticals Industries Ltd., Rockwell Automation Inc., Sun Pharmaceutical Industries Ltd., 3D Systems Corporation, XtalPi Inc., Insilico Medicine Inc.
North America was the largest region in the pharma 5.0 market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pharma 5.0 market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the pharma 5.0 market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The pharma 5.0 market consists of revenues earned by entities by providing services such as remote patient monitoring, quality assurance support, pharmacovigilance services, and virtual healthcare services. The market value includes the value of related goods sold by the service provider or included within the service offering. The pharma 5.0 market consists of sales of personalized medicine products, automated manufacturing equipment, and smart wearable devices for patient monitoring. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Pharma 5.0 Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses pharma 5.0 market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on end user analysis.
Benchmark performance against key competitors based on market share, innovation, and brand strength.
Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for pharma 5.0 ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The pharma 5.0 market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Scope
Markets Covered:1) By Type: Personalized Medicine Platforms; Digital Therapeutics; Artificial Intelligence-Driven Drug Discovery; Smart Manufacturing; Artificial Intelligence-Based Diagnostics
2) By Technology: Cloud Computing; Artificial Intelligence (AI); Machine Learning (ML); Internet of Things (IoT); Robotic Process Automation (RPA)
3) By Deployment Mode: On-Premise; Cloud-Based
4) By Therapeutic Area: Cardiovascular Diseases; Oncology; Infectious Diseases; Neurology; Other Therapeutic Areas
5) By End-User: Pharmaceutical And Biotech Companies; Healthcare Providers; Contract Research Organizations (CROs); Research Institutes
Subsegments:
1) By Personalized Medicine Platforms: Genomic Sequencing; Biomarker Identification; Pharmacogenomics; Patient Data Integration; Precision Drug Formulation
2) By Digital Therapeutics: Mobile Health Applications; Cognitive Behavioral Therapy (CBT) Tools; Chronic Disease Management Software; Remote Monitoring Devices
3) By Artificial Intelligence-Driven Drug Discovery: Target Identification; Molecule Screening; Predictive Toxicology; Drug Repurposing; Clinical Trial Optimization
4) By Smart Manufacturing (Digital Twins and Automation): Process Automation; Digital Twin Simulation; Predictive Maintenance; Quality Control Systems; Robotics In Manufacturing
5) By Artificial Intelligence-Based Diagnostics: Medical Imaging Analysis; Genomic Data Interpretation; Predictive Risk Modeling; Diagnostic Decision Support Systems
Companies Mentioned: Pfizer Incorporated; Johnson & Johnson; Roche Holding AG; Sanofi S.A.; Bristol Myers Squibb Company; AstraZeneca Plc; Novartis AG; GSK Plc; Eli Lilly and Company; Ericsson AB; Merck KGaA; Moderna Inc.; BioNTech SE; Teva Pharmaceuticals Industries Ltd.; Rockwell Automation Inc.; Sun Pharmaceutical Industries Ltd.; 3D Systems Corporation; XtalPi Inc.; Insilico Medicine Inc.
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report
+ Excel Dashboard
Added Benefits
Bi-Annual Data Update
Customisation
Expert Consultant Support
Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.
4.1.2 Digitalization, Cloud, Big Data & Cybersecurity
4.1.3 Biotechnology, Genomics & Precision Medicine
4.1.4 Industry 4.0 & Intelligent Manufacturing
4.1.5 Internet Of Things (Iot), Smart Infrastructure & Connected Ecosystems
4.2. Major Trends
4.2.1 Integration Of Patient-Centric Digital Health Solutions
4.2.2 Growth In Precision Medicine And Personalized Treatment Plans
4.2.3 Adoption Of Smart Manufacturing And Automation In Pharma
4.2.4 Expansion Of Remote Monitoring And Virtual Healthcare Platforms
4.2.5 Increasing Use Of Predictive Analytics For Drug Development And Clinical Trials
5. Pharma 5.0 Market Analysis Of End Use Industries
5.1 Pharmaceutical Companies
5.2 Biotech Companies
5.3 Healthcare Providers
5.4 Contract Research Organizations (Cros)
5.5 Research Institutes
6. Pharma 5.0 Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market
7. Global Pharma 5.0 Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis
7.1. Global Pharma 5.0 PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
7.2. Global Pharma 5.0 Market Size, Comparisons And Growth Rate Analysis
7.3. Global Pharma 5.0 Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
7.4. Global Pharma 5.0 Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)
8. Global Pharma 5.0 Total Addressable Market (TAM) Analysis for the Market
8.1. Definition and Scope of Total Addressable Market (TAM)
8.2. Methodology and Assumptions
8.3. Global Total Addressable Market (TAM) Estimation
8.4. TAM vs. Current Market Size Analysis
8.5. Strategic Insights and Growth Opportunities from TAM Analysis
9. Pharma 5.0 Market Segmentation
9.1. Global Pharma 5.0 Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Personalized Medicine Platforms, Digital Therapeutics, Artificial Intelligence-Driven Drug Discovery, Smart Manufacturing, Artificial Intelligence-Based Diagnostics
9.2. Global Pharma 5.0 Market, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Cloud Computing, Artificial Intelligence (AI), Machine Learning (ML), Internet of Things (IoT), Robotic Process Automation (RPA)
9.3. Global Pharma 5.0 Market, Segmentation By Deployment Mode, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
On-Premise, Cloud-Based
9.4. Global Pharma 5.0 Market, Segmentation By Therapeutic Area, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Cardiovascular Diseases, Oncology, Infectious Diseases, Neurology, Other Therapeutic Areas
9.5. Global Pharma 5.0 Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Pharmaceutical And Biotech Companies, Healthcare Providers, Contract Research Organizations (CROs), Research Institutes
9.6. Global Pharma 5.0 Market, Sub-Segmentation Of Personalized Medicine Platforms, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Genomic Sequencing, Biomarker Identification, Pharmacogenomics, Patient Data Integration, Precision Drug Formulation
9.7. Global Pharma 5.0 Market, Sub-Segmentation Of Digital Therapeutics, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Mobile Health Applications, Cognitive Behavioral Therapy (CBT) Tools, Chronic Disease Management Software, Remote Monitoring Devices
9.8. Global Pharma 5.0 Market, Sub-Segmentation Of Artificial Intelligence-Driven Drug Discovery, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
9.9. Global Pharma 5.0 Market, Sub-Segmentation Of Smart Manufacturing (Digital Twins and Automation), By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Process Automation, Digital Twin Simulation, Predictive Maintenance, Quality Control Systems, Robotics In Manufacturing
9.10. Global Pharma 5.0 Market, Sub-Segmentation Of Artificial Intelligence-Based Diagnostics, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Medical Imaging Analysis, Genomic Data Interpretation, Predictive Risk Modeling, Diagnostic Decision Support Systems
10. Pharma 5.0 Market Regional And Country Analysis
10.1. Global Pharma 5.0 Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
10.2. Global Pharma 5.0 Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
11. Asia-Pacific Pharma 5.0 Market
11.1. Asia-Pacific Pharma 5.0 Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
11.2. Asia-Pacific Pharma 5.0 Market, Segmentation By Type, Segmentation By Technology, Segmentation By Deployment Mode, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
12. China Pharma 5.0 Market
12.1. China Pharma 5.0 Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
12.2. China Pharma 5.0 Market, Segmentation By Type, Segmentation By Technology, Segmentation By Deployment Mode, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
13. India Pharma 5.0 Market
13.1. India Pharma 5.0 Market, Segmentation By Type, Segmentation By Technology, Segmentation By Deployment Mode, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
14. Japan Pharma 5.0 Market
14.1. Japan Pharma 5.0 Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
14.2. Japan Pharma 5.0 Market, Segmentation By Type, Segmentation By Technology, Segmentation By Deployment Mode, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
15. Australia Pharma 5.0 Market
15.1. Australia Pharma 5.0 Market, Segmentation By Type, Segmentation By Technology, Segmentation By Deployment Mode, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
16. Indonesia Pharma 5.0 Market
16.1. Indonesia Pharma 5.0 Market, Segmentation By Type, Segmentation By Technology, Segmentation By Deployment Mode, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
17. South Korea Pharma 5.0 Market
17.1. South Korea Pharma 5.0 Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
17.2. South Korea Pharma 5.0 Market, Segmentation By Type, Segmentation By Technology, Segmentation By Deployment Mode, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
18. Taiwan Pharma 5.0 Market
18.1. Taiwan Pharma 5.0 Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
18.2. Taiwan Pharma 5.0 Market, Segmentation By Type, Segmentation By Technology, Segmentation By Deployment Mode, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
19. South East Asia Pharma 5.0 Market
19.1. South East Asia Pharma 5.0 Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
19.2. South East Asia Pharma 5.0 Market, Segmentation By Type, Segmentation By Technology, Segmentation By Deployment Mode, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
20. Western Europe Pharma 5.0 Market
20.1. Western Europe Pharma 5.0 Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
20.2. Western Europe Pharma 5.0 Market, Segmentation By Type, Segmentation By Technology, Segmentation By Deployment Mode, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
21. UK Pharma 5.0 Market
21.1. UK Pharma 5.0 Market, Segmentation By Type, Segmentation By Technology, Segmentation By Deployment Mode, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
22. Germany Pharma 5.0 Market
22.1. Germany Pharma 5.0 Market, Segmentation By Type, Segmentation By Technology, Segmentation By Deployment Mode, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
23. France Pharma 5.0 Market
23.1. France Pharma 5.0 Market, Segmentation By Type, Segmentation By Technology, Segmentation By Deployment Mode, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
24. Italy Pharma 5.0 Market
24.1. Italy Pharma 5.0 Market, Segmentation By Type, Segmentation By Technology, Segmentation By Deployment Mode, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
25. Spain Pharma 5.0 Market
25.1. Spain Pharma 5.0 Market, Segmentation By Type, Segmentation By Technology, Segmentation By Deployment Mode, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
26. Eastern Europe Pharma 5.0 Market
26.1. Eastern Europe Pharma 5.0 Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
26.2. Eastern Europe Pharma 5.0 Market, Segmentation By Type, Segmentation By Technology, Segmentation By Deployment Mode, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
27. Russia Pharma 5.0 Market
27.1. Russia Pharma 5.0 Market, Segmentation By Type, Segmentation By Technology, Segmentation By Deployment Mode, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
28. North America Pharma 5.0 Market
28.1. North America Pharma 5.0 Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
28.2. North America Pharma 5.0 Market, Segmentation By Type, Segmentation By Technology, Segmentation By Deployment Mode, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
29. USA Pharma 5.0 Market
29.1. USA Pharma 5.0 Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
29.2. USA Pharma 5.0 Market, Segmentation By Type, Segmentation By Technology, Segmentation By Deployment Mode, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
30. Canada Pharma 5.0 Market
30.1. Canada Pharma 5.0 Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
30.2. Canada Pharma 5.0 Market, Segmentation By Type, Segmentation By Technology, Segmentation By Deployment Mode, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
31. South America Pharma 5.0 Market
31.1. South America Pharma 5.0 Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
31.2. South America Pharma 5.0 Market, Segmentation By Type, Segmentation By Technology, Segmentation By Deployment Mode, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
32. Brazil Pharma 5.0 Market
32.1. Brazil Pharma 5.0 Market, Segmentation By Type, Segmentation By Technology, Segmentation By Deployment Mode, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
33. Middle East Pharma 5.0 Market
33.1. Middle East Pharma 5.0 Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
33.2. Middle East Pharma 5.0 Market, Segmentation By Type, Segmentation By Technology, Segmentation By Deployment Mode, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
34. Africa Pharma 5.0 Market
34.1. Africa Pharma 5.0 Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
34.2. Africa Pharma 5.0 Market, Segmentation By Type, Segmentation By Technology, Segmentation By Deployment Mode, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
35. Pharma 5.0 Market Regulatory and Investment Landscape
36. Pharma 5.0 Market Competitive Landscape And Company Profiles
36.1. Pharma 5.0 Market Competitive Landscape And Market Share 2024
36.1.1. Top 10 Companies (Ranked by revenue/share)
36.2. Pharma 5.0 Market - Company Scoring Matrix
36.2.1. Market Revenues
36.2.2. Product Innovation Score
36.2.3. Brand Recognition
36.3. Pharma 5.0 Market Company Profiles
36.3.1. Pfizer Incorporated Overview, Products and Services, Strategy and Financial Analysis
36.3.2. Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
36.3.3. Roche Holding AG Overview, Products and Services, Strategy and Financial Analysis
36.3.4. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
36.3.5. Bristol Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis
37. Pharma 5.0 Market Other Major And Innovative Companies
AstraZeneca Plc, Novartis AG, GSK Plc, Eli Lilly and Company, Ericsson AB, Merck KGaA, Moderna Inc., BioNTech SE, Teva Pharmaceuticals Industries Ltd., Rockwell Automation Inc., Sun Pharmaceutical Industries Ltd., 3D Systems Corporation, XtalPi Inc., Insilico Medicine Inc.
38. Global Pharma 5.0 Market Competitive Benchmarking And Dashboard
39. Key Mergers And Acquisitions In The Pharma 5.0 Market
40. Pharma 5.0 Market High Potential Countries, Segments and Strategies
40.1 Pharma 5.0 Market In 2030 - Countries Offering Most New Opportunities
40.2 Pharma 5.0 Market In 2030 - Segments Offering Most New Opportunities
40.3 Pharma 5.0 Market In 2030 - Growth Strategies
